<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-696
Date of Submission: 2025-01-08

This report was submitted by a Physician from Young-Carson Medical Center concerning patient ANON-PX-5975. The subject is an adult male with a significant medical history including chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intramuscular route at a dosage of 369mg, initiated on 2024-12-30 for Hypercholesterolemia with the course ongoing.

On approximately 2025-01-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Angioedema, Dizziness. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed mother and advised activity. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Art high school card case pull. Pull toward threat direction science early. Break down south perform east.</data>
report_id: ADR-2025-696
report_date: '2025-01-08'
patient_details:
  patient_id: ANON-PX-5975
  gender: Male
  relevant_history:
  - chronic kidney disease
  - anxiety
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 369mg
  route_of_administration: Intramuscular
  start_date: '2024-12-30'
  indication_for_use: Hypercholesterolemia
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2025-01-05'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed mother and advised activity.
- symptom_name: Angioedema
  onset_date: '2025-01-05'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: true
- symptom_name: Dizziness
  onset_date: '2025-01-05'
  severity: Severe
  outcome: Fatal
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
  naranjo_score: 8
reporting_facility: Young-Carson Medical Center
reporter_type: Physician
notes: Art high school card case pull. Pull toward threat direction science early.
  Break down south perform east.
